Link between tumor exosomal PRDX1 in portal-vein blood and post-surgery liver metastasis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective observational cohort where blood will be collected from a branch of the portal/mesenteric vein at the time of curative colorectal cancer resection and exosomes will be isolated for protein analysis focused on PRDX1. Protein mass spectrometry or targeted assays will quantify exosomal PRDX1 and compare portal-derived levels with peripheral measures. Patients will be followed after surgery for development of liver metastasis and results will be correlated with the measured biomarker levels. The team reports preliminary data showing higher PRDX1 in portal-vein–derived blood than in peripheral blood, and the protocol excludes patients with preexisting liver disease, prior anti-tumor therapy, or inability to provide intraoperative portal blood.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age between 19-80 years old, gender not limited;

  * Can comply with the requirements of the research visit plan and other protocols;

    * Voluntarily participate and sign an informed consent form; ④ Diagnosed with colon adenocarcinoma through pathological examination; ⑤ Patients who have completed colorectal radical surgery.

Exclusion Criteria:

* Patients who cannot complete radical surgery for colorectal cancer;

  * Patients with liver diseases (chronic hepatitis B, hepatitis C, severe fatty liver, cirrhosis);

    * Patients who require combined organ resection;

      * Combine patients with other malignant tumors or blood or immune system diseases; ⑤ Prior to tumor resection, any anti-tumor treatment, including radiotherapy, chemotherapy, and molecular targeted therapy, has been performed; ⑥ After surgery, it was found that the mesenteric vein branch of the specimen could not obtain blood due to severe infiltration or other reasons.

        * Patients with severe postoperative complications leading to delayed treatment (Clavien-Dindo grade III or above).

Where it's running

• Shanghai Tongji Hospital, Hepatobilliary Surgery Center, Tongji University
  Shanghai, Shanghai Municipality, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Knife-assisted full-thickness resection for rectal lesions in a multicenter setting

  A multicenter study tests knife-assisted full-thickness resection (kFTR) to remove rectal lesions in adults and see how well it works and how safe it is.

  Recruiting University Hospital, Ghent · Ghent · NCT07923682

• Personalized 3D Bioprinted Colorectal Cancer Microenvironment Model

  This study tests patient-derived, 3D-bioprinted cancer models that include tumor, fibroblast, and immune cells to see if they can better predict how colorectal cancer will respond to treatment.

  Recruiting Peking Union Medical College Hospital · Ningbo, Zhejiang · NCT07919418

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• Prehabilitation with Resistance, Aerobic, or Both Before Colorectal Surgery

  Four pre-surgery exercise options (resistance, aerobic, both, or none) will be tested to see which best reduces complications after colorectal cancer surgery.

  Recruiting Semmelweis University · Budapest · NCT07896174

• Liver transplantation for colorectal cancer with liver metastases

  This study follows adults with stage IV colorectal cancer whose disease is limited to the liver and who are getting a liver transplant as part of their cancer care to see how they fare over time.

  Recruiting Pontificia Universidad Catolica de Chile · Santiago, Santiago Metropolitan · NCT07884110

• LTZ-232: a first-in-human test in advanced colorectal and other solid tumors

  A first-in-human study tests LTZ-232, a new therapy for adults with unresectable or metastatic colorectal cancer and other solid tumors that have not responded to standard treatments.

  Recruiting Phase 1 LTZ Therapeutics, Inc. · Scottsdale, Arizona · NCT07878988

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.